# SR One Capital Management, LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1910264. Source: https://holderbook.com/funds/1910264-sr-one-capital-management-lp/

- Reported value: $1.0B
- Positions: 15
- Weight of the ten largest: 95.1%
- Filed: 2026-08-12

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| VERADERMICS INC | [MANE](https://holderbook.com/stocks/MANE/) | $295.3M | 2,401,868 | 28.4% | 2 |
| ZENAS BIOPHARMA INC | [ZBIO](https://holderbook.com/stocks/ZBIO/) | $127.9M | 5,037,854 | 12.3% | 8 |
| CRISPR THERAPEUTICS AG | [CRSP](https://holderbook.com/stocks/CRSP/) | $111.2M | 2,038,763 | 10.7% | 10 |
| AVALYN PHARMACEUTICALS INC | [AVLN](https://holderbook.com/stocks/AVLN/) | $108.9M | 3,308,649 | 10.5% | 1 |
| DESIGN THERAPEUTICS INC | [DSGN](https://holderbook.com/stocks/DSGN/) | $94.4M | 6,526,476 | 9.1% | 19 |
| ODYSSEY THERAPEUTICS INC | [ODTX](https://holderbook.com/stocks/ODTX/) | $71.0M | 3,794,883 | 6.8% | 1 |
| ALUMIS INC | [ALMS](https://holderbook.com/stocks/ALMS/) | $55.2M | 1,959,896 | 5.3% | 9 |
| ORIC PHARMACEUTICALS INC | [ORIC](https://holderbook.com/stocks/ORIC/) | $50.0M | 4,615,384 | 4.8% | 5 |
| MINERALYS THERAPEUTICS INC | [MLYS](https://holderbook.com/stocks/MLYS/) | $42.2M | 1,563,966 | 4.1% | 14 |
| ARS PHARMACEUTICALS INC | [SPRY](https://holderbook.com/stocks/SPRY/) | $32.1M | 4,012,903 | 3.1% | 15 |
| MOBIA MED INC | - | $26.6M | 1,986,072 | 2.6% | 1 |
| NKARTA INC | [NKTX](https://holderbook.com/stocks/NKTX/) | $9.4M | 3,333,333 | 0.9% | 17 |
| OCULIS HOLDING AG | [OCS](https://holderbook.com/stocks/OCS/) | $8.9M | 641,022 | 0.9% | 6 |
| ULTRAGENYX PHARMACEUTICAL IN | [RARE](https://holderbook.com/stocks/RARE/) | $4.6M | 137,753 | 0.4% | 3 |
| ENGENE HOLDINGS INC | [ENGN](https://holderbook.com/stocks/ENGN/) | $1.3M | 747,750 | 0.1% | 9 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +35.3% | +14.8% | +20.5% | 70% |
| Q1 2026 | +8.1% | -4.6% | +12.7% | 100% |
| Q4 2025 | +2.9% | +2.4% | +0.5% | 100% |
| Q3 2025 | +44.5% | +7.8% | +36.7% | 100% |
| Q2 2025 | +6.7% | +10.5% | -3.7% | 100% |
| Q1 2025 | -10.9% | -4.6% | -6.3% | 100% |
| Q4 2024 | -18.2% | +2.1% | -20.4% | 100% |
| Q3 2024 | +26.7% | +5.4% | +21.3% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $1.0B | 15 |
| Q1 2026 | $915.4M | 14 |
| Q4 2025 | $706.4M | 13 |
| Q3 2025 | $691.4M | 12 |
| Q2 2025 | $461.4M | 13 |
| Q1 2025 | $389.3M | 12 |
| Q4 2024 | $410.1M | 11 |
| Q3 2024 | $498.7M | 11 |
| Q2 2024 | $319.4M | 9 |
| Q1 2024 | $364.1M | 6 |
| Q4 2023 | $238.2M | 5 |
| Q3 2023 | $195.1M | 6 |